• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the January 11, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee

 

FDA

 

Disclaimer

 

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

 

FDA- Bystolic (nebivolol) in Chronic Heart Failure- Briefing Material (pdf)

 

FDA- Bystolic (nebivolol) in Chronic Heart Failure- Errata (pdf)

 

*************************************

 

Forest Research Institute

 

Disclaimer

 

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

 

Forest- Bystolic (nebivolol) in Chronic Heart Failure- Briefing Material (pdf)